Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
Background/Objective: Pemigatinib, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, is a novel therapeutic approach for treating cholangiocarcinoma when an FGFR fusion or gene rearrangement is identified. Although the most reported side effect of pemigatinib is hyperphosphatemia, tumoral ca...
Main Authors: | Akshan Puar, MBBS, Diane Donegan, MD, Paul Helft, MD, Matthew Kuhar, MD, Jonathan Webster, MD, Megana Rao, BS, Michael Econs, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | AACE Clinical Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2376060522000475 |
Similar Items
-
A novel FGF23 mutation in hyperphosphatemic familial tumoral calcinosis and its deleterious effect on protein O-glycosylation
by: Qingyao Zuo, et al.
Published: (2022-09-01) -
New biomarkers of bone remodelling regulation in patients with acromegaly and endogenous hypercortisolism
by: Timur T. Tsoriev, et al.
Published: (2018-10-01) -
FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan
by: Altynay Balmukhanova, et al.
Published: (2020-12-01) -
Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1–2 Chronic Kidney Disease
by: Anita Saxena, et al.
Published: (2022-08-01) -
High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis
by: Yu-Wei Fang, et al.
Published: (2023-04-01)